Table 1.
Baseline characteristics of randomized subjects.
| Buprenorphine n=44 | Naltrexone n=43 | Placebo n=39 | |
|---|---|---|---|
| Age - mean (SD) | 36.3 (9.3) | 38.2 (9.3) | 37.6 (8.2) |
| Malay Ethnicity | 31 (71%) | 28 (65%) | 27 (69.0%) |
| Single | 35 (79.5%) | 32 (74.4%) | 23 (59.0%) |
| HS Education or above | 2 (5%)) | 3 (7%) | 5 (13.0%) |
| Unemployed | 23 (52.3%) | 14 (32.6%) | 14 (35.9%) |
| Lifetime history of incarceration | 28 (63.6%) | 30 (69.8%) | 23 (59.0%) |
| History of previous drug treatment | 21 (47.7%) | 30 (69.8%) | 24 (61.5%) |
| Years of heroin use - mean (SD) | 14.5 (8.0) | 16.4 (9.0) | 14.8 (8.0) |
| Days of heroin use in the past 30 – mean (SD) | 27.0 (6.6) | 26.0 (8.3) | 28.3 (6.2) |
| Lifetime ATS abuse | 26 (59.1%) | 18 (41.9%) | 16 (41.0%) |
| Current ATS abuse | 20 (45.5%) | 17 (39.5%) | 13 (33.3%) |
| Lifetime Benzo abuse | 26 (59.1%) | 25 (58.1%) | 26 (66.7%) |
| Current Benzo abuse | 24 (54.5%) | 21 (48.4%) | 23 (59.0%) |
| Lifetime IDU | 33 (75.0%) | 36 (83.7%) | 31 (79.5%) |
| Current IDU | 20 (46%) | 16 (37%) | 16 (41%) |
| Lifetime needle sharing | 22 (50.0%) | 13 (30.2%) | 22 (56.4%) |
| Current needle sharing (past 30 days) | 14 (31.8%) | 8 (18.6%) | 12 (30.8%) |
| HIV seropositive* | 11 (25.6%) | 11 (26.2%) | 5 (13.2%) |
| Hepatitis C | 39 (88.6%) | 41 (95.3%) | 36 (92.3%) |
| Hepatitis B | 0 (0.0%) | 2 (4.7%) | 5 (12.8%) |
| Pulmonary TB | 5 (11.4%) | 10 (23.3%) | 6 (15.4%) |
| Consistent condom use | 3 (6.8%) | 4 (9.3%) | 2 (5.1%) |
| Multiple concurrent sex partners (lifetime) 17 (38.6%) | 15 (34.8%) | 9 (23.1%) | |